Compare Stocks → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APLTNASDAQ:LTRNNASDAQ:MBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$4.74-1.9%$5.75$0.88▼$9.39$501.92M1.811.98 million shs724,360 shsLTRNLantern Pharma$5.77-3.7%$6.59$2.38▼$11.99$64.34M1.41287,224 shs106,584 shsMBIOMustang Bio$0.37-2.6%$1.04$0.33▼$8.17$3.99M1.58272,377 shs199,542 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics-1.86%-11.24%-24.28%+86.61%+389.11%LTRNLantern Pharma-3.67%-13.49%-22.96%+47.19%+15.40%MBIOMustang Bio-3.39%-32.20%-64.50%-72.52%-90.82%New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics4.759 of 5 stars4.53.00.04.72.63.30.6LTRNLantern Pharma0.1739 of 5 stars0.02.00.00.02.50.80.6MBIOMustang Bio1.6344 of 5 stars3.55.00.00.01.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics3.00Buy$11.60144.73% UpsideLTRNLantern Pharma2.00HoldN/AN/AMBIOMustang Bio3.00Buy$17.254,549.60% UpsideCurrent Analyst RatingsLatest APLT, MBIO, and LTRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.003/26/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.003/15/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/6/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $12.002/22/2024APLTApplied TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/22/2024APLTApplied TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.002/16/2024APLTApplied TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $7.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$9.99M50.24N/AN/A($0.20) per share-23.70LTRNLantern PharmaN/AN/AN/AN/A$3.76 per shareN/AMBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$119.76M-$1.35N/AN/AN/AN/AN/A-275.83%5/9/2024 (Estimated)LTRNLantern Pharma-$15.96M-$1.48N/AN/AN/AN/A-34.11%-32.19%5/14/2024 (Estimated)MBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)Latest APLT, MBIO, and LTRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023LTRNLantern Pharma-$0.40-$0.39+$0.01-$0.39N/AN/A3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/A3/6/2024Q4 2023APLTApplied Therapeutics-$0.15-$0.33-$0.18-$0.33N/A($0.67) millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A0.760.76LTRNLantern PharmaN/A16.1816.18MBIOMustang BioN/A0.740.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%LTRNLantern Pharma28.62%MBIOMustang Bio9.95%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics19.10%LTRNLantern Pharma6.92%MBIOMustang Bio2.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics25105.89 million85.66 millionOptionableLTRNLantern Pharma2110.74 million10.00 millionOptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableAPLT, MBIO, and LTRN HeadlinesSourceHeadlineWorcester biopharmaceutical firm Mustang Bio to lay off 81% of staffwbjournal.com - April 18 at 1:45 PMBiotech cites federal review of deal with Chinese firm in latest staff cutsbizjournals.com - April 16 at 9:03 AMMustang Bio stock tumbles 27% amid news of mass layoffsmsn.com - April 15 at 5:59 PMMustang Bio announces major workforce reductioninvesting.com - April 14 at 11:56 AMMustang Bio to Cut Global Headcount by 81%marketwatch.com - April 12 at 8:56 PMMustang Bio Exploring MB-106 CAR T-Cell Candidate in Autoimmune Diseasesprecisionmedicineonline.com - March 29 at 3:32 PMMustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseasesglobenewswire.com - March 28 at 9:00 AMMustang Bio, City of Hope CAR-T therapy extends survival in phase 1 glioblastoma trialfiercebiotech.com - March 12 at 1:35 PMMustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlightsglobenewswire.com - March 11 at 4:05 PMCAR T-Cell Therapy Shows Activity in Subgroup of Brain Tumor Patientstechnologynetworks.com - March 8 at 8:10 AMMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Gliomatmcnet.com - March 7 at 9:09 AMWhy Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarketmarkets.businessinsider.com - March 7 at 9:09 AMMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Gliomaglobenewswire.com - March 7 at 7:30 AMMustang Bio Inc (MBIO)uk.investing.com - February 13 at 2:36 PMMustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conferencefinance.yahoo.com - January 11 at 9:29 AMMustang Bio Inc MBIOmorningstar.com - January 6 at 12:54 AMMustang Bio Stock (NASDAQ:MBIO) Dividends: History, Yield and Datesbenzinga.com - December 27 at 10:10 PMMBIO Mustang Bio, Inc.seekingalpha.com - December 22 at 10:10 AMMustang Bio: Departure Of Directors Or Certain Officers; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officerscbonds.com - December 14 at 5:42 PMMustang Bio files to sell 2.74M shares of common stock for holdersmsn.com - December 12 at 1:26 PMMustang Bio’s Positive Financial Performance and Promising Clinical Developments Drive Buy Ratingmarkets.businessinsider.com - November 15 at 8:45 PMMustang Bio, Inc.: Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlightsfinanznachrichten.de - November 15 at 3:44 PMMustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meetingfinance.yahoo.com - November 2 at 10:51 AMMustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - October 30 at 3:45 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsApplied TherapeuticsNASDAQ:APLTApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Lantern PharmaNASDAQ:LTRNLantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.